Download PDF
Semin Respir Crit Care Med 2013; 34(06): 787-791
DOI: 10.1055/s-0033-1358555
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Tissue Acquisition and Specimen Processing in the Diagnosis of NSCLC

Jason Akulian
1   Section of Interventional Pulmonology, Division of Pulmonary and Critical Care, University of North Carolina in Chapel Hill, Chapel Hill, North Carolina
,
Lonny Yarmus
2   Section of Interventional Pulmonology, Division of Pulmonary and Critical Care, Johns Hopkins University, Baltimore, Maryland
,
David Feller-Kopman
2   Section of Interventional Pulmonology, Division of Pulmonary and Critical Care, Johns Hopkins University, Baltimore, Maryland
› Author Affiliations
Further Information

Publication History

Publication Date:
20 November 2013 (online)

    Permissions and Reprints

Abstract

The current management of non–small cell lung cancer (NSCLC) requires pathological differentiation between adenocarcinoma and squamous cell carcinoma using immunohistochemistry and morphological analysis. Additionally, as novel therapies for specific genetic mutation and chromosomal rearrangement profiles in patients with adenocarcinoma are becoming more numerous and clinically available, adequate tissue acquisition and specimen processing have become crucial. Historically, tissue was obtained via mediastinoscopy or video-assisted thoracoscopy (VATS). However, 80% of patients with lung cancer are ultimately found to be nonsurgical candidates. More recently, endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been shown to be a safe and potentially superior modality to obtain tissue for diagnosis, staging, and molecular profiling. The preparation of tissue specimens has also been the subject of study as different methods have been shown to increase cellular yield. This is of particular importance as the number of clinically significant targetable mutations and chromosomal rearrangements continues to grow and the need for more tissue increases.

Keywords

lung cancer - non–small cell lung cancer (NSCLC) - mediastinal staging - lymph node - endobronchial ultrasound (EBUS) - epidermal growth factor receptor (EGFR)
 

  • References

  • 1 American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013
    Google Scholar
  • 2 Johnson DH, Fehrenbacher L, Novotny WF , et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22 (11) 2184-2191
    CrossrefPubMedGoogle Scholar
  • 3 Sandler A, Gray R, Perry MC , et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24) 2542-2550
    CrossrefPubMedGoogle Scholar
  • 4 Scagliotti G, Brodowicz T, Shepherd FA , et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011; 6 (1) 64-70
    PubMedGoogle Scholar
  • 5 Tsuta K, Tanabe Y, Yoshida A , et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung. J Thorac Oncol 2011; 6 (7) 1190-1199
    CrossrefPubMedGoogle Scholar
  • 6 Navani N, Brown JM, Nankivell M , et al. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients. Am J Respir Crit Care Med 2012; 185 (12) 1316-1322
    CrossrefPubMedGoogle Scholar
  • 7 Travis WD, Brambilla E, Noguchi M , et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6 (2) 244-285
    CrossrefPubMedGoogle Scholar
  • 8 Coudert B, Ciuleanu T, Park K , et al; SATURN Investigators. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012; 23 (2) 388-394
    CrossrefPubMedGoogle Scholar
  • 9 Mitsudomi T, Morita S, Yatabe Y , et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11 (2) 121-128
    CrossrefPubMedGoogle Scholar
  • 10 Mok TS, Wu YL, Thongprasert S , et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10) 947-957
    CrossrefPubMedGoogle Scholar
  • 11 Koivunen JP, Mermel C, Zejnullahu K , et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008; 14 (13) 4275-4283
    CrossrefPubMedGoogle Scholar
  • 12 Silvestri GA, Gould MK, Margolis ML , et al; American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3, Suppl): 178S-201S
    CrossrefPubMedGoogle Scholar
  • 13 Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA ; American College of Chest Physicians. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132 (3, Suppl): 202S-220S
    CrossrefPubMedGoogle Scholar
  • 14 Erasmus JJ, Sabloff BSCT. CT, positron emission tomography, and MRI in staging lung cancer. Clin Chest Med 2008; 29 (1) 39-57 , v
    CrossrefPubMedGoogle Scholar
  • 15 Medford AR, Bennett JA, Free CM, Agrawal S. Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pulm Med 2009; 15 (4) 334-342
    CrossrefPubMedGoogle Scholar
  • 16 Gilbert C, Yarmus L, Feller-Kopman D. Use of endobronchial ultrasound and endoscopic ultrasound to stage the mediastinum in early-stage lung cancer. J Natl Compr Canc Netw 2012; 10 (10) 1277-1282
    PubMedGoogle Scholar
  • 17 Casal RF, Staerkel GA, Ost D , et al. Randomized clinical trial of endobronchial ultrasound needle biopsy with and without aspiration. Chest 2012; 142 (3) 568-573
    CrossrefPubMedGoogle Scholar
  • 18 Eapen GA, Shah AM, Lei X , et al; American College of Chest Physicians Quality Improvement Registry, Education. Complications, consequences, and practice patterns of endobronchial ultrasound-guided transbronchial needle aspiration: results of the AQuIRE registry. Chest 2013; 143 (4) 1044-1053
    CrossrefPubMedGoogle Scholar
  • 19 Herth FJ. Nonsurgical staging of the mediastinum: EBUS and EUS. Semin Respir Crit Care Med 2011; 32 (1) 62-68
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Silvestri GA, Gonzalez AV, Jantz MA , et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5, Suppl): e211S-e250S
    CrossrefPubMedGoogle Scholar
  • 21 van Eijk R, Licht J, Schrumpf M , et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS ONE 2011; 6 (3) e17791
    CrossrefPubMedGoogle Scholar
  • 22 Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol 2011; 119 (2) 111-117
    CrossrefPubMedGoogle Scholar
  • 23 Nakajima T, Yasufuku K, Suzuki M , et al. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007; 132 (2) 597-602
    CrossrefPubMedGoogle Scholar
  • 24 Schuurbiers OC, Looijen-Salamon MG, Ligtenberg MJ, van der Heijden HF. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 2010; 5 (10) 1664-1667
    CrossrefPubMedGoogle Scholar
  • 25 Sakairi Y, Nakajima T, Yasufuku K , et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res 2010; 16 (20) 4938-4945
    CrossrefPubMedGoogle Scholar
  • 26 Tanner NT, Watson P, Boylan A , et al. Utilizing endobronchial ultrasound with fine-needle aspiration to obtain tissue for molecular analysis: a single-center experience. J Bronchology Interv Pulmonol 2011; 18 (4) 317-321
    CrossrefPubMedGoogle Scholar
  • 27 Diacon AH, Koegelenberg CF, Schubert P , et al. Rapid on-site evaluation of transbronchial aspirates: randomised comparison of two methods. Eur Respir J 2010; 35 (6) 1216-1220
    CrossrefPubMedGoogle Scholar
  • 28 Lee HS, Lee GK, Lee HS , et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station?. Chest 2008; 134 (2) 368-374
    CrossrefPubMedGoogle Scholar
  • 29 Paez JG, Jänne PA, Lee JC , et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304 (5676) 1497-1500
    CrossrefPubMedGoogle Scholar
  • 30 Pao W, Miller V, Zakowski M , et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101 (36) 13306-13311
    CrossrefPubMedGoogle Scholar
  • 31 Lynch TJ, Bell DW, Sordella R , et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350 (21) 2129-2139
    CrossrefPubMedGoogle Scholar
  • 32 Nakajima T, Yasufuku K, Nakagawara A, Kimura H, Yoshino I. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2011; 140 (5) 1319-1324
    CrossrefPubMedGoogle Scholar
  • 33 Trisolini R, Cancellieri A, Tinelli C , et al. Rapid on-site evaluation of transbronchial aspirates in the diagnosis of hilar and mediastinal adenopathy: a randomized trial. Chest 2011; 139 (2) 395-401
    CrossrefPubMedGoogle Scholar
  • 34 Yarmus L, Van der Kloot T, Lechtzin N, Napier M, Dressel D, Feller-Kopman D. A randomized prospective trial of the utility of rapid on-site evaluation of transbronchial needle aspirate specimens. J Bronchology Interv Pulmonol 2011; 18 (2) 121-127
    CrossrefPubMedGoogle Scholar
  • 35 Feller-Kopman D, Yung RC, Burroughs F, Li QK. Cytology of endobronchial ultrasound-guided transbronchial needle aspiration: a retrospective study with histology correlation. Cancer 2009; 117 (6) 482-490
    PubMedGoogle Scholar
  • 36 Yarmus LB, Akulian J, Lechtzin N , et al; American College of Chest Physicians Quality Improvement Registry, Education, and Evaluation (AQuIRE) Participants. Comparison of 21-gauge and 22-gauge aspiration needle in endobronchial ultrasound-guided transbronchial needle aspiration: results of the American College of Chest Physicians Quality Improvement Registry, Education, and Evaluation Registry. Chest 2013; 143 (4) 1036-1043
    CrossrefPubMedGoogle Scholar
  • 37 Nakajima T, Yasufuku K, Takahashi R , et al. Comparison of 21-gauge and 22-gauge aspiration needle during endobronchial ultrasound-guided transbronchial needle aspiration. Respirology 2011; 16 (1) 90-94
    CrossrefPubMedGoogle Scholar
  • 38 Yung RC, Otell S, Illei P , et al. Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration. Cancer Cytopathol 2012; 120 (3) 185-195
    CrossrefPubMedGoogle Scholar
  • 39 Yasufuku K, Chiyo M, Sekine Y , et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes. Chest 2004; 126 (1) 122-128
    CrossrefPubMedGoogle Scholar
  • 40 Yu HA, Arcila ME, Rekhtman N , et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19 (8) 2240-2247
    CrossrefPubMedGoogle Scholar
  • 41 Vincent MD, Kuruvilla MS, Leighl NB, Kamel-Reid S. Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol 2012; 19 (Suppl. 01) S33-S44
    PubMedGoogle Scholar
  • 42 Lindeman NI, Cagle PT, Beasley MB , et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8 (7) 823-859
    CrossrefPubMedGoogle Scholar